Skip to main content
SpringerLink
Log in

Aktuelle Therapie des trockenen Auges

Current treatment for dry eye syndrome

  • Leitthema
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Zusammenfassung

Die Therapie des trockenen Auges als die einer chronischen Erkrankung bedarf eines langfristigen therapeutischen Bündnisses zwischen Arzt und Patient. Ziel ist die Reduktion der Beschwerden mit einem erträglichen Therapieaufwand von Seiten des Patienten. Das therapeutische Stufenkonzept umfasst Tränenersatzmittel, Eigenserumaugentropfen, Punctum-Plugs, neue antientzündliche Augentropfen (Ciclosporin A 0,05%) sowie chirurgische Ansätze. Eine interdisziplinäre Betreuung, am besten in einer Sicca-Spezialsprechstunde mit Qualitätskontrolle, garantiert eine möglichst optimale Patientenversorgung.

Abstract

The therapy of dry eye disease as a chronic problem necessitates a long-term therapeutic association between patient and ophthalmologist. The aim of therapy is to relieve symptoms and improve vision as far as possible with an acceptable level of effort on the part of the patient. Therapy of dry eye follows a staged concept including tear replacement, serum eye drops, punctum plugs, novel anti-inflammatory drugs (cyclosporin A), and surgical procedures. Interdisciplinary care, especially of patients with autoimmune disease, is recommended and is best provided in a specialized dry eye outpatient clinic with quality control.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4

Literatur

  1. American Academy of Ophthalmology (2003) Preferred Practice Pattern: Dry Eye Syndrome

    Google Scholar 

  2. Avunduk AM, Avunduk MC, Varnell ED, Kaufmann HE (2003) The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 136:593–602

    Article  PubMed  Google Scholar 

  3. Balaram M, Schaumberg D, Dana MR (2001) Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol 131:30–36

    Article  PubMed  Google Scholar 

  4. Barabino S, Rolando M, Camicione P, Ravera G, Zanardi S, Giuffrida S, Calabria G (2003) Systemic linolenic and gamma-linolenic acid therapy in dry eye syndrome with an inflammatory component. Cornea 22:97–101

    Article  PubMed  Google Scholar 

  5. Baudouin C, Brignole F, Pisella PJ, De Saint Jean M, Goguel A (2002) Flow cytometric analysis of the inflammatory marker HLA-DR in dry eye syndrome: results from 12 months of randomized treatment with topical cyclosporin A. Adv Exp Med Biol 506:761–769

    PubMed  Google Scholar 

  6. Baudouin C, Hamard P, Liang H, Creuzot-Garcher C, Bensoussan L, Brignole F (2004) Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 111:2186–2192

    Article  PubMed  Google Scholar 

  7. Brignole F, Pisella PJ, De Saint Jean M, Goldschild M, Goguel A, Baudouin C (2001) Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporin A. Invest Ophthalmol Vis Sci 42:90–95

    PubMed  Google Scholar 

  8. Cursiefen C, Jacobi C, Dietrich T, Seitz B, Schlötzer-Schrehardt U, Kruse FE (2005) [Tear film-based identification and therapy of the immune pathogenesis of dry eye disease (dysfunctional tear syndrome)]. DOG, Berlin

  9. Cursiefen C, Seitz B, Kruse FE (2005) Neurotrophe Keratopathie: Pathogenese, Klinik und Therapie. Ophthalmologe 102:7–14

    Article  PubMed  Google Scholar 

  10. Demmler M, de Kaspar HM, Mohring C, Klauss V (1997) [Blepharitis. Demodex folliculorum, associated pathogen spectrum and specific therapy]. Ophthalmologe 94:191–196

    Article  PubMed  Google Scholar 

  11. Hanisch KT, Neppert B, Geerling G (2005) [Gas permeable scleral lenses as a conservative treatment option for extreme corneal ectasias and severe dry eye]. Ophthalmologe 102:387–392

    Article  PubMed  Google Scholar 

  12. Jacobi C, Cursiefen C, Kruse FE (2006) [Etiology and diagnosis of dry eye syndrome]. Ophthalmologe 2006, im Druck

  13. Jackson RS, Van Duyken SJ, Mc Cartney MD, Ubels JL (2001) The eicosanoid, 15-(S)-HETE, stimulates secretion of mucin-like glycoprotein by the corneal epithelium. Cornea 20:516–521

    Article  PubMed  Google Scholar 

  14. Jaksche A (2005) [Undiluted versus diluted autologous serum eye drops: a prospective, randomized, double-blind study in patients with refractory dry eye-syndrome]. DOG, Berlin

  15. Johnson ME, Murphy PJ (2004) Changes in the tear film and ocular surface from dry eye syndrome. Prog Retin Eye Res 23:449–474

    Article  PubMed  Google Scholar 

  16. Kojima T, Ishida R, Dogru M, Goto E, Matsumoto Y, Kaido M, Tsubota K (2005) The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol 139:242–246

    Article  PubMed  Google Scholar 

  17. Kruse FE (2002) Therapie des trockenen Auges. In: Kampik A, Grehn F (Hrsg) Augenärztliche Therapie. Thieme, Stuttgart, S 359

  18. Kruse FE, Seitz B, Cursiefen C (2005) Oberflächenstörungen des Auges. In: Kampik A, Grehn F (2005) Augenärztliche Rehabilitation. Thieme, Stuttgart, S 103

  19. Liu L, Hartwig D, Harloff S, Herminghaus P, Wedel T, Geerling G (2005) An optimised protocol for the production of autologous serum eyedrops. Graefes Arch Clin Exp Ophthalmol 243:706–714

    Article  PubMed  Google Scholar 

  20. Murube J (2003) Surgical treatment of dry eye. Orbit 22:203–232

    Article  PubMed  Google Scholar 

  21. Murube J, Murube E (1996) Treatment of dry eye by blocking the lacrimal canaliculi. Surv Ophthalmol 40:463–480

    Article  PubMed  Google Scholar 

  22. Nichols KK, Yerxa B, Kellerman DJ (2004) Diquafosol tetrasodium: a novel dry eye therapy. Expert Opin Investig Drugs 13:47–54

    Article  PubMed  Google Scholar 

  23. Perry HD, Donnenfeld ED (2004) Dry eye diagnosis and management in 2004. Curr Opin Ophthalmol 15:299–304

    Article  PubMed  Google Scholar 

  24. Pflugfelder SC (2004) Antiinflammatory therapy for dry eye. Am J Ophthalmol 137:337–342

    Article  PubMed  Google Scholar 

  25. Scheuerle AF, Kruse FE (2004) [Treatment of „dry eyes“]. Med Monatsschr Pharm 27:199–207

    PubMed  Google Scholar 

  26. Schirra F, Suzuki T, Richards SM et al. (2005) Androgen control of gene expression in the mouse meibomian gland. Invest Ophthalmol Vis Sci 46:3666–3675

    Article  PubMed  Google Scholar 

  27. Schirra F, Ruprecht KW (2004) [Dry eye. An update on epidemiology, diagnosis, therapy and new concepts.] Ophthalmologe 101:10–18

    Google Scholar 

  28. Seitz B, Grüterich M, Cursiefen C, Kruse FE (2005) Konservative und chirurgische Therapie der neurotrophen Keratopathie. Ophthalmologe 102:15–26

    Article  PubMed  Google Scholar 

  29. Stevenson D, Tauber J, Reis BL (2000) Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 107:967–974

    Article  PubMed  Google Scholar 

  30. Sullivan DA, Yamagami H, Liu M et al. (2002) Sex steroids, the meibomian gland and evaporative dry eye. Adv Exp Med Biol 506:389–399

    PubMed  Google Scholar 

  31. Smith RE (2005) The tear film complex: pathogenesis and emerging therapies for dry eyes. Cornea 24:1–7

    Article  PubMed  Google Scholar 

  32. Wilson SE (2003) Inflammation: a unifying theory for the origin of dry eye syndrome. Manag Care 12:14–19

    Google Scholar 

Download references

Interessenkonflikt:

Es besteht kein Interessenkonflikt. Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen. Die Präsentation des Themas ist unabhängig und die Darstellung der Inhalte produktneutral.

Author information

Authors and Affiliations

  1. Augenklinik mit Poliklinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen

    C. Cursiefen, C. Jacobi, T. Dietrich & F. E. Kruse

  2. Augenklinik mit Poliklinik, Friedrich-Alexander-Universität Erlangen-Nürnberg, Schwabachanlage 6, 91054 , Erlangen

    C. Cursiefen

Authors
  1. C. Cursiefen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Jacobi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T. Dietrich
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F. E. Kruse
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Cursiefen.

Additional information

Unterstützung: Sicca-Forschungsförderung des Ressorts Trockenes Auge des BVA (DOG 2005); Interdisziplinäres Zentrum für Klinische Forschung (IZKF) Erlangen (A9).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cursiefen, C., Jacobi, C., Dietrich, T. et al. Aktuelle Therapie des trockenen Auges. Ophthalmologe 103, 18–24 (2006). https://doi.org/10.1007/s00347-005-1300-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-005-1300-9

Schlüsselwörter

Keywords

Search

Navigation